We report for the first time that RBPJL (p.P476S) promotes tumor growth in ESCC and inhibits the efficacy of anti‐PD‐1 therapy through blunting T‐cell responses. This evidence concerns the gene RBPJL and esophageal squamous cell carcinoma.